Overview

Study of Lorlatinib in ROS1 Rearranged NSCLC

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea